VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Lactobacillus rhamnosus X253
Preclinical
Biologic
J
Junlebao Dairy Group Co., Ltd.
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Probiotics
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Probiotics
Preclinical
Completed
Clinical
Trials by Indication
[1]
Probiotics
1 trial
Research on the Characteristics and Application of Lactobacillus Rhamnosus X253 as Oral Probiotics
Completed
·
J
Junlebao Dairy Group Co., Ltd.
·
N/A
·
NCT05123651
·
60 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Lactobacillus rhamnosus X253. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Lactobacillus rhamnosus X253 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Lactobacillus rhamnosus X253. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Junlebao Dairy Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Preclinical
[1]
Company
J
Junlebao Dairy Group Co., Ltd.
Related News